€2282m market cap
€40.7 last close
Laboratorios Farmacéuticos ROVI is a fully integrated Spanish speciality pharmaceutical company that is developing, manufacturing and marketing small molecule and speciality biologic drugs, with expertise in low molecular weight heparin (LMWH). Its drugs pipeline is focused on its proprietary ISM technology.
Investment summary
ROVI is a profitable speciality healthcare company that markets ~40 proprietary and in-licensed products across nine core franchises, mainly in its domestic Spanish market. Since obtaining market authorisation for its internally developed enoxaparin biosimilar (Becat) in multiple countries, ROVI has commenced marketing in several European countries and has signed out-licensing agreements that cover 91 countries globally – key drivers for sales and operating growth in the medium term. In September 2019, ROVI announced that it plans to build a new LMWH manufacturing facility over the next three years, doubling its current capacity. R&D progress continues with its proprietary ISM technology. Following positive PRISMA-3 data on DORIA (risperidone ISM), a long-acting injectable for schizophrenia, an MAA was filed with the EMA in January 2020 leading to a potential launch in Europe in 2021. The US NDA was filed in November 2020.
Y/E Dec |
Revenue (€m) |
EBITDA (€m) |
PBT (€m) |
EPS (c) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2018A | 304.8 | 29.5 | 19.2 | 38.45 | 105.9 | 239.7 |
| 2019A | 382.5 | 60.9 | 45.6 | 76.64 | 53.1 | N/A |
| 2020E | 402.6 | 79.9 | 63.3 | 102.55 | 39.7 | 761.1 |
| 2021E | 425.8 | 71.5 | 54.2 | 87.51 | 46.5 | 41.5 |
Industry outlook
ROVI has a strong presence in the Spanish heparin market (and select international markets through partners), where it has been manufacturing and marketing its flagship product, Hibor (second-generation LMWH), since 1998.
Last updated on 27/01/2021
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net debt (€m) | 58.2 |
| Forecast gearing ratio (%) | 16 |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Javier Lopez-Belmonte Encina | CFO |
| Marta Campos Martinez | Investor Relations |
Content on Laboratorios Farmacéuticos ROVI
You may also be interested in…
- 4SC
- Abliva
- Acacia Pharma
- Acarix
- ADL Bionatur Solutions
- Adocia
- Allarity Therapeutics
- ASIT biotech
- Basilea Pharmaceutica
- BerGenBio
- BioPorto Diagnostics
- Bonesupport
- Brighter
- Cantargia
- Carmat
- Celyad
- Deinove
- Formycon
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- Kiadis Pharma
- MagForce
- Medigene
- MOLOGEN
- Nanobiotix
- Newron Pharmaceuticals
- Nicox
- Nuevolution
- Oasmia Pharmaceutical
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Pharnext
- Photocure
- Pixium Vision
- Polyphor
- Probiodrug
- Quantum Genomics
- RhoVac
- Ryvu Therapeutics
- Targovax
- Transgene
- TxCell
- Xbrane Biopharma